TEMPE, ARIZ.— Arizona State University announced an agreement Tuesday with Brigham Young University-Idaho and BYU-Pathway Worldwide to facilitate the transfer of academic credit for students wishing to complete a degree at ASU.
"ASU, BYU-Idaho, and BYU-Pathway share a common mission and purpose: to help students achieve their educational and career goals," said ASU President Michael M. Crow. "We do that by bringing them into higher education and working hard to ensure they are successful in the completion of their college degree - no matter where they start the process."
The Guaranteed Program for Admission (GPA) will help students plan a smooth transfer to ASU and stay focused on earning a bachelor's degree. This program is designed for students who achieve between 24 and 60 transferrable lower-division credits with a minimum of a 2.5 grade-point average for most majors. It is a cost-effective and time-efficient way of ensuring courses transfer and apply to an ASU degree.
The Associate of Applied Science to Bachelor of Applied Science (AAS to BAS) program is for students who have completed an Associate of Applied Science from BYU-Idaho and want to complete a Bachelor of Applied Science at ASU. BYU-Idaho students who complete their AAS will receive 60 credits in transfer toward a complementary BAS degree at ASU, thus requiring a maximum of 60 additional credits to complete their BAS at ASU.
"The strength of the relationship is that both ASU and BYU-Idaho are deeply committed to student success," said Maria Hesse, ASU's vice provost for academic partnerships. "Our primary goal is to facilitate a seamless transition from one institution to the other, so that students can pursue their personal and professional aspirations.
"BYU-Pathway Worldwide operates the Pathway program and also offers online degrees and certificates developed in partnership with BYU-Idaho. Pathway is a one-year educational curriculum designed to give students the confidence and skills needed to succeed in college. It is run by The Church of Jesus Christ of Latter-day Saints and is a low-cost educational opportunity that combines online courses with weekly gatherings in hundreds of church communities around the world, including the Phoenix metropolitan area.
"We are pleased to be partnering with ASU in ways that will increase access and opportunity for our BYU-Pathway students" said BYU-Pathway President Clark Gilbert. "ASU has been a great friend to our program, and we look forward to offering local options for students in Arizona who want to take advantage of these opportunities."
For Arizonans who wish to continue their education beyond Pathway and are interested in a major not available through BYU-Idaho, the relationship with ASU may be particularly attractive, offering students the ability to transfer credit to ASU for the work they've already done and attend classes in person or online.
Students signing up for either the GPA or AAS to BAS programs will receive access to a transfer specialist and pre-enrollment services at ASU. They will also be able to use tools such as ASU's online major maps, which provide a detailed outline to critical requirements in a chosen field of study.
"He's also a great supporter of BYU-Idaho," Eyring said. "He has inspired confidence in our innovations, both on campus and online."
Crow's address focused on how we as individuals can make an affirmative choice to improve ourselves and the world around us, and he asked the students in attendance to spend some time thinking about what they want to contribute.
"What is your unique improvement?" Crow asked the crowd. "... What are you going to do to improve what you've been given?"
*This news release was distributed by Arizona State University.


High School sports have the ability to bring communities together. This communal bonding is due to in large part to students and members of the area congregating at primetime hours to watch their friends and family compete in sports representing the town. If Novato High were to add lights like our neighbors at San Marin, there could be a large increase in support and enthusiasm for the teams of Novato High.
San Marin recently got approved to add lights to their stadium. They gained approval in a hotly-contested community vote. Many of the neighbors surrounding San Marin High School were strongly against the idea of having lights, largely due to the fears of loud noise and light pollution.
Novato High is located in a residential area and many neighbors seem to also be largely against installing field lights.
Greg Fister is Novato High School's Assistant Principal and interim Athletic Director.
Many students at Novato High seem to be strongly in favor of installing field lights.
Roya Manshouri is a junior cheerleader at Novato High and believes lights would help create more spirit.
The installation of field lights would benefit all sports that use the artificial-turf field. Varsity sports, such as lacrosse and soccer, are forced to play their games at 4:30 or earlier, due to concerns about daylight running out. This early start time is a conflict, as the American workday does not end until 5 p.m., making it extremely difficult or impossible for many parents to support their children's teams.
Longtime social studies teacher and former varsity football coach Jason Searle provided some insight on this topic.
Searle also described some of the challenges NHS has faced with attempting to put in field lights.
The idea of bringing field lights to Novato High is not a new one. The Marin IJ previously reported that the NUSD board of trustees considered adding lights to both Novato high schools in 2009. However, this stirred up controversy in the community. In 2009, this idea was supported by the funds needed coming from a $107 million bond that was passed by residents of Novato. This is important because Novato recently passed a $222 million bond measure (Measure G), that was meant to upgrade academic and athletic facilities. San Marin's new field lights and an upgraded public-address system are expected to cost under 1.3 million dollars. This is worth every penny. Novato High should have strongly considered doing the same thing.


text:
Label: PIMECROLIMUS cream
Packager: Oceanside Pharmaceuticals
Marketing Status: New Drug Application Authorized Generic
These highlights do not include all the information needed to use PIMECROLIMUS safely and effectively. See full prescribing information for PIMECROLIMUS.
PIMECROLIMUS cream, for topical use
WARNING: LONG-TERM SAFETY OF TOPICAL CALCINEURIN INHIBITORS HAS NOT BEEN ESTABLISHED
Although a causal relationship has not been established, rare cases of malignancy (e.g., skin and lymphoma) have been reported in patients treated with topical calcineurin inhibitors, including Pimecrolimus Cream, 1%. (5.1)
Continuous long-term use of topical calcineurin inhibitors, including Pimecrolimus Cream, 1%, in any age group should be avoided and application limited to areas of involvement with atopic dermatitis. (2, 5.1)
Pimecrolimus Cream, 1% is not indicated for use in children less than 2 years of age. (1, 5.1, 8.4)
Pimecrolimus Cream, 1% is a calcineurin inhibitor immunosuppressant indicated as second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable. (1)
Apply a thin layer of Pimecrolimus Cream, 1% to the affected skin twice daily. (2)
If signs and symptoms persist beyond 6 weeks, patients should be re-examined. (2)
Continuous long-term use of Pimecrolimus Cream, 1% should be avoided. (2)
Avoid use with occlusive dressings. (2)
Cream, 1%. (3)
Pimecrolimus Cream, 1% is contraindicated in individuals with a history of hypersensitivity to pimecrolimus or any of the components of the cream. (4, 6.2)
Should not be used in immunocompromised adults and children, including patients on systemic immunosuppressive medications. (5.1)
Avoid treatment on malignant or pre-malignant skin conditions, as these can present as dermatitis. (5.2)
Should not be used in patients with Netherton's Syndrome or skin diseases with a potential for increased systemic absorption. (5.2)
The most commonly reported adverse reactions (≥1%) were application site burning, headache, nasopharyngitis, cough, influenza, pyrexia and viral infection. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Oceanside Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
5.1 Risk of Immunosuppression
5.2	Application to Malignant or Pre-malignant Skin Conditions
5.3	Bacterial and Viral Skin Infections
5.4	Patients with Lymphadenopathy
5.5	Sun Exposure
5.6	Immunocompromised Patients
8.3 Nursing Mothers
Although a causal relationship has not been established, rare cases of malignancy (e.g., skin and lymphoma) have been reported in patients treated with topical calcineurin inhibitors, including Pimecrolimus Cream, 1%. [see Warnings and Precautions (5.1)].
Continuous long-term use of topical calcineurin inhibitors, including Pimecrolimus Cream, 1%, in any age group should be avoided and application limited to areas of involvement with atopic dermatitis [see Dosage and Administration (2), Warnings and Precautions (5.1)].
Pimecrolimus Cream, 1% is not indicated for use in children less than 2 years of age [see Warnings and Precautions (5.1), Use in Specific Populations (8.4)].
Pimecrolimus Cream, 1% is indicated as second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable.
Pimecrolimus Cream, 1% is not indicated for use in children less than 2 years of age[see Warnings and Precautions (5.1), Use in Specific Populations (8.4)].
Apply a thin layer of Pimecrolimus Cream, 1% to the affected skin twice daily. The patient should stop using Pimecrolimus Cream, 1% when signs and symptoms (e.g., itch, rash and redness) resolve and should be instructed on what actions to take if symptoms recur.
If signs and symptoms persist beyond 6 weeks, patients should be re-examined by their healthcare provider to confirm the diagnosis of atopic dermatitis.
Continuous long-term use of Pimecrolimus Cream, 1% should be avoided, and application should be limited to areas of involvement with atopic dermatitis [see Warnings and Precautions (5.1)].
The safety of Pimecrolimus Cream, 1% under occlusion, which may promote systemic exposure, has not been evaluated. Avoid use of Pimecrolimus Cream, 1% with occlusive dressings.
Cream, 1%.
Each gram of Pimecrolimus Cream, 1% contains 10 mg of pimecrolimus in a whitish cream base.
Pimecrolimus Cream, 1% is contraindicated in individuals with a history of hypersensitivity to pimecrolimus or any of the components of the cream.
Prolonged systemic use of calcineurin inhibitors for sustained immunosuppression in animal studies and transplant patients following systemic administration has been associated with an increased risk of infections, lymphomas, and skin malignancies. These risks are associated with the intensity and duration of immunosuppression.
Based on this information and the mechanism of action, there is a concern about a potential risk with the use of topical calcineurin inhibitors, including Pimecrolimus Cream, 1%. While a causal relationship has not been established, rare cases of skin malignancy and lymphoma have been reported in patients treated with topical calcineurin inhibitors, including Pimecrolimus Cream, 1%. Therefore:
Continuous long-term use of topical calcineurin inhibitors, including Pimecrolimus Cream, 1%, in any age group should be avoided, and application limited to areas of involvement with atopic dermatitis.
Pimecrolimus Cream, 1% is not indicated for use in children less than 2 years of age.
Pimecrolimus Cream, 1% should not be used in immunocompromised adults and children, including patients on systemic immunosuppressive medications.
If signs and symptoms of atopic dermatitis do not improve within 6 weeks, patients should be re-examined by their healthcare provider and their diagnosis be confirmed.
The safety of Pimecrolimus Cream, 1% has not been established beyond 1 year of non-continuous use.
The use of Pimecrolimus Cream, 1% should be avoided on malignant or pre-malignant skin conditions. Malignant or pre-malignant skin conditions, such as cutaneous T-cell lymphoma (CTCL), can present as dermatitis.
Pimecrolimus Cream, 1% should not be used in patients with Netherton's Syndrome or other skin diseases where there is the potential for increased systemic absorption of pimecrolimus. The safety of Pimecrolimus Cream, 1% has not been established in patients with generalized erythroderma.
The use of Pimecrolimus Cream, 1% may cause local symptoms such as skin burning (burning sensation, stinging, soreness) or pruritus. Localized symptoms are most common during the first few days of Pimecrolimus Cream, 1% application and typically improve as the lesions of atopic dermatitis resolve [see Adverse Reactions (6.1)].
Before commencing treatment with Pimecrolimus Cream, 1%, bacterial or viral infections at treatment sites should be resolved. Trials have not evaluated the safety and efficacy of Pimecrolimus Cream, 1% in the treatment of clinically infected atopic dermatitis.
While patients with atopic dermatitis are predisposed to superficial skin infections including eczema herpeticum (Kaposi's varicelliform eruption), treatment with Pimecrolimus Cream, 1% may be independently associated with an increased risk of varicella zoster virus infection (chickenpox or shingles), herpes simplex virus infection, or eczema herpeticum.
In clinical trials, 15/1544 (1%) cases of skin papilloma (warts) were observed in subjects using Pimecrolimus Cream, 1%. The youngest subject was age 2 and the oldest was age 12. In cases where there is worsening of skin papillomas or they do not respond to conventional therapy, discontinuation of Pimecrolimus Cream, 1% should be considered until complete resolution of the warts is achieved.
In clinical trials, 14/1544 (0.9%) cases of lymphadenopathy were reported while using Pimecrolimus Cream, 1%. These cases of lymphadenopathy were usually related to infections and noted to resolve upon appropriate antibiotic therapy. Of these 14 cases, the majority had either a clear etiology or were known to resolve. Patients who receive Pimecrolimus Cream, 1% and who develop lymphadenopathy should have the etiology of their lymphadenopathy investigated. In the absence of a clear etiology for the lymphadenopathy, or in the presence of acute infectious mononucleosis, Pimecrolimus Cream, 1% should be discontinued. Patients who develop lymphadenopathy should be monitored to ensure that the lymphadenopathy resolves.
During the course of treatment, it is prudent for patients to minimize or avoid natural or artificial sunlight exposure, even while Pimecrolimus Cream, 1% is not on the skin. The potential effects of Pimecrolimus Cream, 1% on skin response to ultraviolet damage are not known.
The safety and efficacy of Pimecrolimus Cream, 1% in immunocompromised patients have not been studied.
No phototoxicity and no photoallergenicity were detected in clinical trials with 24 and 33 normal volunteers, respectively. In human dermal safety trials, Pimecrolimus Cream, 1% did not induce contact sensitization or cumulative irritation.
In a 1-year safety trial in pediatric subjects age 2-17 years old involving sequential use of Pimecrolimus Cream, 1% and a topical corticosteroid, 43% of Pimecrolimus Cream, 1% treated subjects and 68% of vehicle-treated subjects used corticosteroids during the trial. Corticosteroids were used for more than 7 days by 34% of Pimecrolimus Cream, 1% treated subjects and 54% of vehicle-treated subjects. An increased incidence of impetigo, skin infection, superinfection (infected atopic dermatitis), rhinitis, and urticaria were found in the subjects that had used Pimecrolimus Cream, 1% and topical corticosteroid sequentially as compared to Pimecrolimus Cream, 1% alone.
In three randomized, double-blind vehicle-controlled pediatric trials and one active-controlled adult trial, 843 and 328 subjects, respectively, were treated with Pimecrolimus Cream, 1%. In these clinical trials, 48 (4%) of the 1171 Pimecrolimus Cream, 1% treated subjects and 13 (3%) of 408 vehicle-treated subjects discontinued therapy due to adverse events. Discontinuations for AEs were primarily due to application site reactions and cutaneous infections. The most common application site reaction was application site burning, which occurred in 8%-26% of subjects treated with Pimecrolimus Cream, 1%.
Table 1 depicts the incidence of adverse events pooled across the two identically designed 6-week trials with their open label extensions and the 1-year safety trial for pediatric subjects ages 2-17. Data from the adult active-controlled trial are also included in Table 1. Adverse events are listed regardless of relationship to trial drug.
Table 1. Treatment Emergent Adverse Events (≥1%) in Pimecrolimus Cream, 1% Treatment Groups
Pediatric Subjects*
Vehicle-Controlled
(6 weeks)
Open-Label
(1 year)
Adult Active Comparator
(20 weeks)
Pimecrolimus Cream, 1%
(N=267)
Ages 2-17 years
At least 1 AE
Infections and Infestations
Upper Respiratory Tract Infection NOS
Skin Infection NOS
Ear Infection NOS
Bacterial Infection
Pneumonia NOS
Pharyngitis NOS
Pharyngitis Streptococcal
Staphylococcal Infection
Bronchitis NOS
Tonsillitis NOS
Viral Infection NOS
Gastroenteritis NOS
Skin Papilloma
Tonsillitis Acute NOS
Upper Respiratory Tract Infection Viral NOS
Herpes Simplex Dermatitis
Bronchitis Acute NOS
Eye Infection NOS
General Disorders and Administration Site Conditions
Application Site Burning
Application Site Reaction NOS
Application Site Irritation
Influenza-Like Illness
Application Site Erythema
Application Site Pruritus
Rhinorrhea
Asthma Aggravated
Asthma NOS
Dyspnea NOS
Abdominal Pain Upper
Vomiting NOS
Diarrhea NOS
Abdominal Pain NOS
Reproductive System and Breast Disorders
Conjunctivitis NEC
Acne NOS
Hypersensitivity NOS
Accident NOS
Musculoskeletal, Connective Tissue and Bone Disorders
Arthralgias
Ear and Labyrinth Disorders
Two cases of septic arthritis have been reported in infants less than one year of age in clinical trials conducted with Pimecrolimus Cream, 1% (n = 2443). Causality has not been established.
The following adverse reactions have been identified during post-approval use of Pimecrolimus Cream, 1%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
General: Anaphylactic reactions, ocular irritation after application of the cream to the eye lids or near the eyes, angioneurotic edema, facial edema, skin flushing associated with alcohol use, skin discoloration.
Hematology/Oncology: Lymphomas, basal cell carcinoma, malignant melanoma, squamous cell carcinoma.
Potential interactions between Pimecrolimus Cream, 1% and other drugs, including immunizations, have not been systematically evaluated. Due to low blood levels of pimecrolimus detected in some patients after topical application, systemic drug interactions are not expected, but cannot be ruled out. The concomitant administration of known CYP3A family of inhibitors in patients with widespread and/or erythrodermic disease should be done with caution. Some examples of such drugs are erythromycin, itraconazole, ketoconazole, fluconazole, calcium channel blockers and cimetidine.
Pregnancy Category C
There are no adequate and well-controlled studies with Pimecrolimus Cream, 1% in pregnant women. Therefore, Pimecrolimus Cream, 1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
In dermal embryofetal developmental studies, no maternal or fetal toxicity was observed up to the highest practicable doses tested, 10 mg/kg/day (1% pimecrolimus cream) in rats (0.14X MRHD based on body surface area) and 10 mg/kg/day (1% pimecrolimus cream) in rabbits (0.65X MRHD based on AUC comparisons). The 1% pimecrolimus cream was administered topically for 6 hours/day during the period of organogenesis in rats and rabbits (gestational days 6-21 in rats and gestational days 6-20 in rabbits).
A second dermal embryofetal development study was conducted in rats using pimecrolimus cream applied dermally to pregnant rats (1 g cream/kg body weight of 0.2%, 0.6% and 1.0% pimecrolimus cream) from gestation day 6 to 17 at doses of 2, 6, and 10 mg/kg/day with daily exposure of approximately 22 hours. No maternal, reproductive, or embryofetal toxicity attributable to pimecrolimus was noted at 10 mg/kg/day (0.66X MRHD based on AUC comparisons), the highest dose evaluated in this study. No teratogenicity was noted in this study at any dose.
A combined oral fertility and embryofetal developmental study was conducted in rats and an oral embryofetal developmental study was conducted in rabbits. Pimecrolimus was administered during the period of organogenesis (2 weeks prior to mating until gestational day 16 in rats, gestational days 6-18 in rabbits) up to dose levels of 45 mg/kg/day in rats and 20 mg/kg/day in rabbits. In the absence of maternal toxicity, indicators of embryofetal toxicity (post-implantation loss and reduction in litter size) were noted at 45 mg/kg/day (38X MRHD based on AUC comparisons) in the oral fertility and embryofetal developmental study conducted in rats. No malformations in the fetuses were noted at 45 mg/kg/day (38X MRHD based on AUC comparisons) in this study. No maternal toxicity, embryotoxicity or teratogenicity were noted in the oral rabbit embryofetal developmental toxicity study at 20 mg/kg/day (3.9X MRHD based on AUC comparisons), which was the highest dose tested in this study.
A second oral embryofetal development study was conducted in rats. Pimecrolimus was administered during the period of organogenesis (gestational days 6 – 17) at doses of 2, 10 and 45 mg/kg/day. Maternal toxicity, embryolethality and fetotoxicity were noted at 45 mg/kg/day (271X MRHD based on AUC comparisons). A slight increase in skeletal variations that were indicative of delayed skeletal ossification was also noted at this dose. No maternal toxicity, embryolethality or fetotoxicity were noted at 10 mg/kg/day (16X MRHD based on AUC comparisons). No teratogenicity was noted in this study at any dose.
A second oral embryofetal development study was conducted in rabbits. Pimecrolimus was administered during the period of organogenesis (gestational days 7 – 20) at doses of 2, 6 and 20 mg/kg/day. Maternal toxicity, embryotoxicity and fetotoxicity were noted at 20 mg/kg/day (12X MRHD based on AUC comparisons). A slight increase in skeletal variations that were indicative of delayed skeletal ossification was also noted at this dose. No maternal toxicity, embryotoxicity or fetotoxicity were noted at 6 mg/kg/day (5X MRHD based on AUC comparisons). No teratogenicity was noted in this study at any dose.
An oral peri- and postnatal developmental study was conducted in rats. Pimecrolimus was administered from gestational day 6 through lactational day 21 up to a dose level of 40 mg/kg/day. Only 2 of 22 females delivered live pups at the highest dose of 40 mg/kg/day. Postnatal survival, development of the F1 generation, their subsequent maturation and fertility were not affected at 10 mg/kg/day (12X MRHD based on AUC comparisons), the highest dose evaluated in this study.
Pimecrolimus was transferred across the placenta in oral rat and rabbit embryofetal developmental studies.
It is not known whether this drug is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from pimecrolimus, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
The long-term safety and effects of Pimecrolimus Cream, 1% on the developing immune system are unknown.
Three Phase 3 pediatric trials were conducted involving 1114 subjects 2-17 years of age. Two trials were 6-week randomized vehicle-controlled trials with a 20-week open-label phase and one was a vehicle-controlled (up to 1 year) safety trial with the option for sequential topical corticosteroid use. Of these subjects, 542 (49%) were 2-6 years of age. In the short-term trials, 11% of Pimecrolimus subjects did not complete these trials and 1.5% of Pimecrolimus subjects discontinued due to adverse events. In the 1-year trial, 32% of Pimecrolimus subjects did not complete this trial and 3% of Pimecrolimus subjects discontinued due to adverse events. Most discontinuations were due to unsatisfactory therapeutic effect.
The most common local adverse event in the short-term trials of Pimecrolimus Cream, 1% in pediatric subjects ages 2-17 was application site burning (10% vs. 13% vehicle); the incidence in the long-term trial was 9% Pimecrolimus vs. 7% vehicle [see Adverse Reactions (6.1)]. Adverse events that were more frequent (>5%) in subjects treated with Pimecrolimus Cream, 1% compared to vehicle were headache (14% vs. 9%) in the short-term trial. Nasopharyngitis (26% vs. 21%), influenza (13% vs. 4%), pharyngitis (8% vs. 3%), viral infection (7% vs. 1%), pyrexia (13% vs. 5%), cough (16% vs. 11%), and headache (25% vs. 16%) were increased over vehicle in the 1-year safety trial [see Adverse Reactions (6.1)]. In 843 subjects ages 2-17 years treated with Pimecrolimus Cream, 1%, 9 (0.8%) developed eczema herpeticum (5 on Pimecrolimus Cream, 1% alone and 4 on Pimecrolimus Cream, 1% used in sequence with corticosteroids). In 211 subjects on vehicle alone, there were no cases of eczema herpeticum. The majority of adverse events were mild to moderate in severity.
Two Phase 3 trials were conducted involving 436 infants age 3 months-23 months. One 6-week randomized vehicle-controlled trial with a 20-week open-label phase and one safety trial, up to one year, were conducted. In the 6-week trial, 11% of Pimecrolimus and 48% of vehicle subjects did not complete this trial; no subject in either group discontinued due to adverse events. Infants on Pimecrolimus Cream, 1% had an increased incidence of some adverse events compared to vehicle. In the 6-week vehicle-controlled trial, these adverse events included pyrexia (32% vs. 13% vehicle), URI (24% vs. 14%), nasopharyngitis (15% vs. 8%), gastroenteritis (7% vs. 3%), otitis media (4% vs. 0%), and diarrhea (8% vs. 0%). In the open-label phase of the trial, for infants who switched to Pimecrolimus Cream, 1% from vehicle, the incidence of the above-cited adverse events approached or equaled the incidence of those subjects who remained on Pimecrolimus Cream, 1%. In the 6-month safety data, 16% of Pimecrolimus and 35% of vehicle subjects discontinued early and 1.5% of Pimecrolimus and 0% of vehicle subjects discontinued due to adverse events. Infants on Pimecrolimus Cream, 1% had a greater incidence of some adverse events as compared to vehicle. These included pyrexia (30% vs. 20%), URI (21% vs. 17%), cough (15% vs. 9%), hypersensitivity (8% vs. 2%), teething (27% vs. 22%), vomiting (9% vs. 4%), rhinitis (13% vs. 9%), viral rash (4% vs. 0%), rhinorrhea (4% vs. 0%), and wheezing (4% vs. 0%).
The systemic exposure to pimecrolimus from Pimecrolimus Cream, 1% was investigated in 28 pediatric subjects with atopic dermatitis (20%-80% BSA involvement) between the ages of 8 months-14 years. Following twice daily application for 3 weeks, blood concentrations of pimecrolimus were <2 ng/mL with 60% (96/161) of the blood samples having blood concentration below the limit of quantification (0.5 ng/mL). However, more children (23 children out of the total 28 children investigated) had at least one detectable blood level as compared to the adults (12 adults out of the total 52 adults investigated) over a 3-week treatment period. Due to the erratic nature of the blood levels observed, no correlation could be made between amount of cream, degree of BSA involvement, and blood concentrations. In general, the blood concentrations measured in adult atopic dermatitis subjects were comparable to those seen in the pediatric population.
In a second group of 30 pediatric subjects aged 3-23 months with 10%-92% BSA involvement, following twice daily application for 3 weeks, blood concentrations of pimecrolimus were <2.6 ng/mL with 65% (75/116) of the blood samples having blood concentration below 0.5 ng/mL, and 27% (31/116) below the limit of quantification (0.1 ng/mL) for these trials.
Overall, a higher proportion of detectable blood levels was seen in the pediatric subject population as compared to adult population. This increase in the absolute number of positive blood levels may be due to the larger surface area to body mass ratio seen in these younger subjects. In addition, a higher incidence of upper respiratory symptoms/infections was also seen relative to the older age group in the PK trials. At this time, a causal relationship between these findings and Pimecrolimus use cannot be ruled out.
Nine (9) subjects ≥65 years old received Pimecrolimus Cream, 1% in Phase 3 trials. Clinical trials of Pimecrolimus Cream, 1% did not include sufficient numbers of subjects aged 65 and over to assess efficacy and safety.
Pimecrolimus Cream, 1%, for topical use, contains the compound pimecrolimus, the immunosuppressant 33-epi-chloro-derivative of the macrolactam ascomycin.
Chemically, pimecrolimus is (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-12-[(1E)-2-{(1R,3R,4S)-4-chloro-3-methoxycyclohexyl}-1-methylvinyl]-17-ethyl-1, 14-dihydroxy-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetraone. The compound has the empirical formula C43H68ClNO11 and the molecular weight of 810.47. The structural formula is:
Pimecrolimus is a white to off-white fine crystalline powder. It is soluble in methanol and ethanol and insoluble in water.
Each gram of Pimecrolimus Cream, 1% contains 10 mg of pimecrolimus in a whitish cream base of benzyl alcohol, cetyl alcohol, citric acid anhydrous, mono- and diglycerides, oleyl alcohol, propylene glycol, sodium cetostearyl sulphate, sodium hydroxide, stearyl alcohol, triglycerides and water.
The mechanism of action of pimecrolimus in atopic dermatitis is not known. While the following have been observed, the clinical significance of these observations in atopic dermatitis is not known. It has been demonstrated that pimecrolimus binds with high affinity to macrophilin-12 (FKBP-12) and inhibits the calcium-dependent phosphatase, calcineurin. As a consequence, it inhibits T-cell activation by blocking the transcription of early cytokines. In particular, pimecrolimus inhibits at nanomolar concentrations Interleukin-2 and interferon gamma (Th1-type) and Interleukin-4 and Interleukin-10 (Th2-type) cytokine synthesis in human T-cells. In addition, pimecrolimus prevents the release of inflammatory cytokines and mediators from mast cells in vitro after stimulation by antigen/IgE.
In adult subjects (n=52) being treated for atopic dermatitis [13%-62% Body Surface Area (BSA) involvement] for periods up to a year, a maximum pimecrolimus concentration of 1.4 ng/mL was observed among those subjects with detectable blood levels. In the majority of samples in adult (91%; 1244/1362) subjects, blood concentrations of pimecrolimus were below 0.5 ng/mL. Data on blood levels of pimecrolimus measured in pediatric subjects are described in Use in Specific Populations (8.4).
Laboratory in vitro plasma protein binding studies using equilibrium gel filtration have shown that 99.5% of pimecrolimus in plasma is bound to proteins over the pimecrolimus concentration range of 2-100 ng/mL tested. The major fraction of pimecrolimus in plasma appears to be bound to various lipoproteins. As with other topical calcineurin inhibitors, it is not known whether pimecrolimus is absorbed into cutaneous lymphatic vessels or in regional lymph nodes.
Following the administration of a single oral radiolabeled dose of pimecrolimus, numerous circulating O-demethylation metabolites were seen. Studies with human liver microsomes indicate that pimecrolimus is metabolized in vitro by the CYP3A subfamily of metabolizing enzymes. No evidence of skin mediated drug metabolism was identified in vivo using the minipig or in vitro using stripped human skin.
Based on the results of the aforementioned radiolabeled study, following a single oral dose of pimecrolimus, ~81% of the administered radioactivity was recovered, primarily in the feces (78.4%) as metabolites. Less than 1% of the radioactivity found in the feces was due to unchanged pimecrolimus.
In a 2-year rat dermal carcinogenicity study using Pimecrolimus Cream, 1%, a statistically significant increase in the incidence of follicular cell adenoma of the thyroid was noted in low, mid and high dose male animals compared to vehicle and saline control male animals. Follicular cell adenoma of the thyroid was noted in the dermal rat carcinogenicity study at the lowest dose of 2 mg/kg/day [0.2% pimecrolimus cream; 1.5X the Maximum Recommended Human Dose (MRHD) based on AUC comparisons]. No increase in the incidence of follicular cell adenoma of the thyroid was noted in the oral carcinogenicity study in male rats up to 10 mg/kg/day (66X MRHD based on AUC comparisons). However, oral studies may not reflect continuous exposure or the same metabolic profile as by the dermal route. In a mouse dermal carcinogenicity study using pimecrolimus in an ethanolic solution, no increase in incidence of neoplasms was observed in the skin or other organs up to the highest dose of 4 mg/kg/day (0.32% pimecrolimus in ethanol) 27X MRHD based on AUC comparisons. However, lymphoproliferative changes (including lymphoma) were noted in a 13-week repeat dose dermal toxicity study conducted in mice using pimecrolimus in an ethanolic solution at a dose of 25 mg/kg/day (47X MRHD based on AUC comparisons). No lymphoproliferative changes were noted in this study at a dose of 10 mg/kg/day (17X MRHD based on AUC comparison). However, the latency time to lymphoma formation was shortened to 8 weeks after dermal administration of pimecrolimus dissolved in ethanol at a dose of 100 mg/kg/day (179-217X MRHD based on AUC comparisons).
In a mouse oral (gavage) carcinogenicity study, a statistically significant increase in the incidence of lymphoma was noted in high dose male and female animals compared to vehicle control male and female animals. Lymphomas were noted in the oral mouse carcinogenicity study at a dose of 45 mg/kg/day (258-340X MRHD based on AUC comparisons). No drug-related tumors were noted in the mouse oral carcinogenicity study at a dose of 15 mg/kg/day (60-133X MRHD based on AUC comparisons).
In an oral (gavage) rat carcinogenicity study, a statistically significant increase in the incidence of benign thymoma was noted in 10 mg/kg/day pimecrolimus treated male and female animals compared to vehicle control treated male and female animals. In addition, a significant increase in the incidence of benign thymoma was noted in another oral (gavage) rat carcinogenicity study in 5 mg/kg/day pimecrolimus treated male animals compared to vehicle control treated male animals. No drug-related tumors were noted in the rat oral carcinogenicity study at a dose of 1 mg/kg/day male animals (1.1X MRHD based on AUC comparisons) and at a dose of 5 mg/kg/day for female animals (21X MRHD based on AUC comparisons).
In a 52-week dermal photocarcinogenicity study, the median time to onset of skin tumor formation was decreased in hairless mice following chronic topical dosing with concurrent exposure to UV radiation (40 weeks of treatment followed by 12 weeks of observation) with the Pimecrolimus Cream, 1% vehicle alone. No additional effect on tumor development beyond the vehicle effect was noted with the addition of the active ingredient, pimecrolimus, to the vehicle cream.
A 39-week oral monkey toxicology study was conducted with pimecrolimus doses of 15, 45 and 120 mg/kg/day. A dose-dependent increase in expression of immunosuppressive-related lymphoproliferative disorder (IRLD) associated with lymphocryptovirus (a monkey strain of virus related to human Epstein Barr virus) was observed. IRLD in monkeys mirrors what has been noted in human transplant patients after chronic systemic immunosuppressive therapy, post-transplantation lymphoproliferative disease (PTLD), after treatment with chronic systemic immunosuppressive therapy. Both IRLD and PTLD can progress to lymphoma, which is dependent on the dose and duration of systemic immunosuppressive therapy. A dose-dependent increase in opportunistic infections (a signal of systemic immunosuppression) was also noted in this monkey study. A no observed adverse effect level (NOAEL) for IRLD and opportunistic infections was not established in this study. IRLD occurred at the lowest dose of 15 mg/kg/day for 39 weeks [31X the Maximum Recommended Human Dose (MRHD) of Pimecrolimus Cream, 1% based on AUC comparisons] in this study. A partial recovery from IRLD was noted upon cessation of dosing in this study.
A battery of in vitro genotoxicity tests, including Ames assay, mouse lymphoma L5178Y assay, and chromosome aberration test in V79 Chinese hamster cells and an in vivo mouse micronucleus test revealed no evidence for a mutagenic or clastogenic potential for the drug.
An oral fertility and embryofetal developmental study in rats revealed estrus cycle disturbances, post-implantation loss and reduction in litter size at the 45 mg/kg/day dose (38X MRHD based on AUC comparisons). No effect on fertility in female rats was noted at 10 mg/kg/day (12X MRHD based on AUC comparisons). No effect on fertility in male rats was noted at 45 mg/kg/day (23X MRHD based on AUC comparisons), which was the highest dose tested in this study.
A second oral fertility and embryofetal developmental study in rats revealed reduced testicular and epididymal weights, reduced testicular sperm counts and motile sperm for males and estrus cycle disturbances, decreased corpora lutea, decreased implantations and viable fetuses for females at 45 mg/kg/day dose (123X MRHD for males and 192X MRHD for females based on AUC comparisons). No effect on fertility in female rats was noted at 10 mg/kg/day (5X MRHD based on AUC comparisons). No effect on fertility in male rats was noted at 2 mg/kg/day (0.7X MRHD based on AUC comparisons).
Three randomized, double-blind, vehicle-controlled, multi-center, Phase 3 trials were conducted in 589 pediatric subjects ages 3 months-17 years old to evaluate Pimecrolimus Cream, 1% for the treatment of mild to moderate atopic dermatitis. Two of the three trials support the use of Pimecrolimus Cream, 1% in subjects 2 years and older with mild to moderate atopic dermatitis [see Warnings and Precautions (5.1)]. Three other trials in 1619 pediatric and adult subjects provided additional data regarding the safety of Pimecrolimus Cream, 1% in the treatment of atopic dermatitis. Two of these other trials were vehicle-controlled with optional sequential use of a medium potency topical corticosteroid in pediatric subjects and one trial was an active comparator trial in adult subjects with atopic dermatitis [see Warnings and Precautions (5.1)and Adverse Reactions (6.1)].
Two identical 6-week, randomized, vehicle-controlled, multi-center, Phase 3 trials were conducted to evaluate Pimecrolimus Cream, 1% for the treatment of mild to moderate atopic dermatitis. A total of 403 pediatric subjects 2-17 years old were included in the trials. The male/female ratio was approximately 50% and 29% of the subjects were African American. At trial entry, 59% of subjects had moderate disease and the mean body surface area (BSA) affected was 26%. About 75% of subjects had atopic dermatitis affecting the face and/or neck region. In these trials, subjects applied either Pimecrolimus Cream, 1% or vehicle cream twice daily to 5% to 96% of their BSA for up to 6 weeks. At endpoint, based on the physician's global evaluation of clinical response, 35% of subjects treated with Pimecrolimus Cream, 1% were clear or almost clear of signs of atopic dermatitis compared to only 18% of vehicle-treated subjects. More Pimecrolimus subjects (57%) had mild or no pruritus at 6 weeks compared to vehicle subjects (34%). The improvement in pruritus occurred in conjunction with the improvement of the subjects' atopic dermatitis.
In these two 6-week trials of Pimecrolimus Cream, 1%, the combined efficacy results at endpoint are presented in Table 2 as follows:
Table 2. Combined Efficacy Results at Endpoint for Two 6-week Trials of Pimecrolimus Cream, 1%
% Subjects
Pimecrolimus Cream, 1% (N=267)
Vehicle (N=136)
Global Assessment
Clear or Almost Clear
Clear to Mild Disease
In the two pediatric trials that independently support the use of Pimecrolimus Cream, 1% in mild to moderate atopic dermatitis, a significant treatment effect was seen by day 15. Of the key signs of atopic dermatitis, erythema, infiltration/papulation, lichenification, and excoriations were reduced at day 8 when compared to vehicle.
Figure 1 depicts the time course of improvement in the percent body surface area affected as a result of treatment with Pimecrolimus Cream, 1% in 2-17 year olds.
Figure 2 shows the time course of improvement in erythema as a result of treatment with Pimecrolimus Cream, 1% in 2-17 year olds.
Pimecrolimus Cream, 1% is a whitish cream available in tubes of 30 grams, 60 grams, and 100 grams.
30 gram tube
100 gram tube
Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Do not freeze.
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Patients using Pimecrolimus Cream, 1% should receive the following information and instructions:
Pimecrolimus Cream, 1% may cause serious side effects. It is not known if Pimecrolimus Cream, 1% is safe to use for a long period of time. A very small number of people who have used Pimecrolimus Cream, 1% have had cancer (for example, skin or lymphoma). However, a link with Pimecrolimus Cream, 1% use has not been shown. Because of this concern:
A patient should not use Pimecrolimus Cream, 1% continuously for a long time.
Pimecrolimus Cream, 1% should be used only on areas of skin that have eczema.
Pimecrolimus Cream, 1% is not for use on a child under 2 years old.
A patient should not use sun lamps, tanning beds, or get treatment with ultraviolet light therapy during treatment with Pimecrolimus Cream, 1%.
A patient should limit sun exposure during treatment with Pimecrolimus Cream, 1% even when the medicine is not on the skin. If a patient needs to be outdoors after applying Pimecrolimus Cream, 1%, the patient should wear loose fitting clothing that protects the treated area from the sun. The physician should advise the patient about other types of protection from the sun.
A patient should not cover the skin being treated with bandages, dressings or wraps. A patient can wear normal clothing.
Pimecrolimus Cream, 1% is for use on the skin only. Do not get Pimecrolimus Cream, 1% in your eyes, nose, mouth, vagina, or rectum (mucous membranes). If you get Pimecrolimus Cream, 1% in any of these areas, burning or irritation can happen. Wipe off any Pimecrolimus Cream, 1% from the affected area and then rinse the area well with cold water. Pimecrolimus Cream, 1% is for external use only.
A patient should use Pimecrolimus Cream, 1% for short periods, and if needed, treatment may be repeated with breaks in between.
Wash hands before using Pimecrolimus Cream, 1%. When applying Pimecrolimus Cream, 1% after a bath or shower, the skin should be dry.
Apply a thin layer of Pimecrolimus Cream, 1% only to the affected skin areas, twice a day, as directed by the physician.
Use the smallest amount of Pimecrolimus Cream, 1% needed to control the signs and symptoms of eczema.
A patient should not bathe, shower or swim right after applying Pimecrolimus Cream, 1%. This could wash off the cream.
A patient can use moisturizers with Pimecrolimus Cream, 1%. They should be sure to check with the physician first about the products that are right for them. Because the skin of patients with eczema can be very dry, it is important they keep up good skin care practices. If a patient uses moisturizers, he or she should apply them after Pimecrolimus Cream, 1%.
Oceanside Pharmaceuticals, a division of
Bausch Health US, LLC
Bridgewater, NJ 08807 USA
Bausch Health Companies Inc.
Laval, Quebec H7L 4A8, Canada
© 2020 Bausch Health Companies Inc. or its affiliates
Important: Pimecrolimus Cream, 1% is for use on the skin only (topical). Do not get Pimecrolimus Cream, 1% in your eyes, nose, mouth, vagina, or rectum.
What is the most important information I should know about Pimecrolimus Cream, 1%?
It is not known if Pimecrolimus Cream, 1% is safe to use for a long period of time. A very small number of people who have used Pimecrolimus Cream, 1% have developed cancer (for example, skin cancer or lymphoma). But a link that Pimecrolimus Cream, 1% use caused these cancers has not been shown. Because of this concern:
Do not use Pimecrolimus Cream, 1% continuously for a long time.
Use Pimecrolimus Cream, 1% only on areas of your skin that have eczema.
Do not use Pimecrolimus Cream, 1% on a child under 2 years of age.
What is Pimecrolimus Cream, 1%?
Pimecrolimus Cream, 1% is a prescription medicine used on the skin (topical) to treat mild to moderate eczema (atopic dermatitis). Pimecrolimus Cream, 1% is for adults and children age 2 years and older who do not have a weakened immune system. Pimecrolimus Cream, 1% is used on the skin for short periods, and if needed, treatment may be repeated with breaks in between. Pimecrolimus Cream, 1% is for use after other prescription medicines have not worked for you or if your doctor recommends that other prescription medicines should not be used.
It is not known if Pimecrolimus Cream, 1% is safe and effective in people who have a weakened immune system.
Pimecrolimus Cream, 1% is not for use in children under 2 years of age.
Who should not use Pimecrolimus Cream, 1%?
Do not use Pimecrolimus Cream, 1% if you are allergic to pimecrolimus or any of the ingredients in Pimecrolimus Cream, 1%. See the end of this Medication Guide for a complete list of ingredients in Pimecrolimus Cream, 1%.
What should I tell my doctor before using Pimecrolimus Cream, 1%?
Before using Pimecrolimus Cream, 1%, tell your doctor about all of your medical conditions, including if you:
have a skin disease called Netherton's syndrome (a rare inherited condition).
have any infection on your skin including chickenpox or herpes.
have been told you have a weakened immune system.
are pregnant or plan to become pregnant. It is not known if Pimecrolimus Cream, 1% will harm your unborn baby.
are breastfeeding or plan to breastfeed. It is not known if Pimecrolimus Cream, 1% passes into your breast milk. You and your doctor should decide if you will use Pimecrolimus Cream, 1% or breastfeed. You should not do both.
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tell your doctor about all the skin medicines and products you use.
Know the medicines you take. Keep a list of them with you to show your doctor and pharmacist each time you get a new medicine.
How should I use Pimecrolimus Cream, 1%?
Use Pimecrolimus Cream, 1% exactly as your doctor tells you to use it.
Stop Pimecrolimus Cream, 1% when the signs and symptoms of eczema, such as itching, rash, and redness go away, or as directed by your doctor.
Wash your hands before using Pimecrolimus Cream, 1%. If you apply Pimecrolimus Cream, 1% after a bath or shower, make sure your skin is dry.
Apply a thin layer of Pimecrolimus Cream, 1% only to the affected skin areas, two times each day, as directed by your doctor.
Use the smallest amount of Pimecrolimus Cream, 1% to help control the signs and symptoms of eczema.
If you apply Pimecrolimus Cream, 1% to another person, or if you have eczema and are not treating your hands, it is important for you to wash your hands with soap and water after applying Pimecrolimus Cream, 1%. This should remove any cream left on your hands.
Do not bathe, shower or swim right after applying Pimecrolimus Cream, 1%. This could wash off the cream.
You can use moisturizers with Pimecrolimus Cream, 1%. Ask your doctor first about the products that are right for you. People with eczema can have very dry skin, so it is important to keep up good skin care practices. If you use moisturizers, apply them after Pimecrolimus Cream, 1%.
Call your doctor if your symptoms get worse with Pimecrolimus Cream, 1% or your symptoms do not improve after 6 weeks of treatment.
What should I avoid while using Pimecrolimus Cream, 1%?
You should not use sun lamps, tanning beds, or get treatment with ultraviolet light therapy during treatment with Pimecrolimus Cream, 1%.
Limit your time in the sun during treatment with Pimecrolimus Cream, 1% even when the medicine is not on your skin. If you need to be outdoors after applying Pimecrolimus Cream, 1%, wear loose fitting clothing that protects the treated area from the sun. Ask your doctor what other types of protection from the sun you should use. It is not known how Pimecrolimus Cream, 1% may affect your skin with exposure to ultraviolet light.
Do not cover the skin being treated with bandages, dressings or wraps. You can wear normal clothing.
Pimecrolimus Cream, 1% is for use on the skin only. Do not get Pimecrolimus Cream, 1% in your eyes, nose, mouth, vagina, or rectum (mucous membranes). If you get Pimecrolimus Cream, 1% in any of these areas, burning or irritation can happen. Wipe off any Pimecrolimus Cream, 1% from the affected area and then rinse the area well with cold water.
Do not swallow Pimecrolimus Cream, 1%. If you do, call your doctor.
Avoid using Pimecrolimus Cream, 1% on skin areas that have cancers or pre-cancers.
What are the possible side effects of Pimecrolimus Cream, 1%?
Pimecrolimus Cream, 1% may cause serious side effects.
See "What is the most important information I should know about Pimecrolimus Cream, 1%?"
The most common side effect at the skin application site is burning or a feeling of warmth. These side effects are usually mild or moderate, happen during the first few days of treatment, and usually clear up in a few days.
Other common side effects include:
common cold or stuffy nose, sore throat
flu (influenza)
viral infection. Some people may get viral skin infections (like cold sores, chickenpox, shingles, or warts) or swollen lymph nodes (glands).
Tell your doctor if you get a skin infection or if you have any side effect (for example, swollen glands) that bothers you or that does not go away.
These are not all the possible side effects with Pimecrolimus Cream, 1%. Ask your doctor or pharmacist for more information.
How should I store Pimecrolimus Cream, 1%?
Store Pimecrolimus Cream, 1% at room temperature between 68° to 77°F (20° to 25°C).
Do not freeze Pimecrolimus Cream, 1%.
Keep Pimecrolimus Cream, 1% and all medicines out of the reach of children.
General information about the safe and effective use of Pimecrolimus Cream, 1%
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Pimecrolimus Cream, 1% for conditions other than which it was prescribed. Do not give Pimecrolimus Cream, 1% to other people even if they have the same symptoms you have. It may harm them.
You can ask your doctor or pharmacist for information about Pimecrolimus Cream, 1% that is written for health professionals.
For more information, call 1-800-321-4576.
What are the ingredients in Pimecrolimus Cream, 1%?
Active ingredient: pimecrolimus
Inactive ingredients: benzyl alcohol, cetyl alcohol, citric acid anhydrous, mono- and diglycerides, oleyl alcohol, propylene glycol, sodium cetostearyl sulphate, sodium hydroxide, stearyl alcohol, triglycerides and water
This Medication Guide has been approved by the U.S. Food and Drug Administration.
Rev. 09/2020 9645301
PRINCIPAL DISPLAY PANEL - 100 g Carton
PIMECROLIMUS CREAM
FOR TOPICAL USE ONLY.
NOT FOR OPHTHALMIC USE.
If PIMECROLIMUS CREAM gets in your eyes,
rinse your eyes with cold water.
ATTENTION PHARMACIST:
Each patient is required to receive
the enclosed Medication Guide.
Net Wt. 100 g
PRINCIPAL DISPLAY PANEL - 60 g Carton
Net Wt. 60 g
PIMECROLIMUS
Pimecrolimus (UNII: 7KYV510875) (Pimecrolimus - UNII:7KYV510875) Pimecrolimus 10 mg in 1 g
BENZYL ALCOHOL (UNII: LKG8494WBH)
CETYL ALCOHOL (UNII: 936JST6JCN)
GLYCERYL MONOSTEARATE (UNII: 230OU9XXE4)
OLEYL ALCOHOL (UNII: 172F2WN8DV)
PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
SODIUM CETOSTEARYL SULFATE (UNII: 7ZBS06BH4B)
SODIUM HYDROXIDE (UNII: 55X04QC32I)
STEARYL ALCOHOL (UNII: 2KR89I4H1Y)
WATER (UNII: 059QF0KO0R)
100 g in 1 TUBE; Type 0: Not a Combination Product
NDA authorized generic NDA021302 11/26/2018
60 g in 1 TUBE; Type 0: Not a Combination Product
Labeler - Oceanside Pharmaceuticals (832011691)
Novartis Pharma GmbH 333288046 MANUFACTURE(68682-112, 68682-111, 68682-110)
Bausch Health Companies Inc. 245141858 MANUFACTURE(68682-112, 68682-111, 68682-110) , PACK(68682-112, 68682-111, 68682-110) , LABEL(68682-112, 68682-111, 68682-110)
1 562806 pimecrolimus 1 % Topical Cream PSN
2 562806 pimecrolimus 10 MG/ML Topical Cream SCD
3 562806 pimecrolimus 1 % Topical Cream SY
https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=6601e43e-ce7d-446a-8568-8e7b24b86f06

redpajama_set_name: RedPajamaCommonCrawl


text:
Update non-compiled information (release notes, authors list, license, etc.) without complete rebuild
Asked by kosist,
kosist
Release notes are written in the build specification. When, for example, developer realizes that some note should be added - package has to be rebuilt. But sometimes build of the package could take a lot of time (for example, build of our DBT toolkit takes approx. 1 hour with licensing, password protecting and further build).
It would be great if there will be option to update just release notes, or another information which should not be compiled (authors list, etc.). That would help to save some time... But on the other side, developer should pay some more attention to build configuration before actually building the toolkit...


text:
Home>The Business
Special Report: Safety
ATTI, Lytx Deal Shines Light on Driver Safety
TAGS: Safety Archive Haulers Business Operations Special Report: Safety
Megan Greenwalt | Mar 17, 2015
Haulers often turn to programs and technologies to help promote driver safety. Now, even the industry's insurance carriers have begun offering incentives to haulers that utilize those technologies as a way to encourage safe driving practices.
Last week, the American Trucking and Transportation Insurance Company, a Risk Retention Group (ATTIC,RRG), Missoula, Mt.-based motor carrier-owned risk retention group, signed an agreement with Lytx Inc., a fleet management solution and GPS vehicle tracking system, to provide Lytx's DriveCam video-based safety program to its large truck clients.
"Our shareholders have invested in their safety performance and believe that owning their own insurance company will have long-term benefit," says Ken Crippen, president and CEO of ATTIC, RRG. "Each motor carrier maintains a large deductible and then a portion of all losses of the group above those deductibles. This puts an emphasis on safety, which led us to Lytx and their DriveCam product."
Greg Lund, director of corporate communications for Lytx, based in San Diego, says under the agreement announced last week, ATTIC will pay for a portion of its members' cost of the Lytx DC Highway Program under the exclusive agreement signed last week.
"It will give our members excellent driver coaching opportunities and help us in managing liability and defense costs in accidents," Crippen says. "We expect the dollar savings from the use of the product to exceed the costs in the long run."
ATTIC, RRG insures about 5,200 trucks nationally. Currently one member has signed up and another is completing a trial of DriveCam.
"I hope that over the next few years more will sign up," says Crippen.
The Lytx DriveCam program is designed to reduce collisions by identifying risk and coaching the driver before those risks lead to a crash.
It "identifies and prioritizes risk so fleets can focus on the drivers who need the most coaching," Lund says.
A device is placed on a vehicle's windshield to capture video of risky driving events such as hard-braking, cornering, and following too close. The device then uploads that information wirelessly to the Lytx Review Center. There, certified professionals objectively review and score the events and pass them on to the fleet for use in coaching drivers.
The device continually records driving data and provides continuous feedback to the driver. Additionally, video and audio—focused on the road outside the vehicle and on the driver—are continually recorded on a short loop but only stored when the vehicle exceeds a preset threshold. Recorded video and audio includes up to eight seconds before an event and four seconds after, according to Lund.
"The program is highly successful in the waste industry because of the fact that heavy vehicles are used and mistakes can have serious consequences," he says. "Often these vehicles are in metropolitan areas with heavy traffic, both human and vehicular. Driver behavior improvement can make a significant difference."
Several of the largest waste companies use the Lytx DriveCam program including Waste Management, Waste Connections, Advanced Disposal and Progressive, according to Lund.
Jeff Martin, vice president of Waste Management's Safety Services, says the Houston-based company uses the Lytx DriveCam technology to further refine and coach drivers' safe driving practices.
"Events are sent to route managers for coaching opportunities. Waste Management route managers and drivers then review the event together and discuss how the drivers can further develop safe driving skills," he says. "It is important to remember that these same events are used for recognition, where a driver responded defensively to mitigate a potential collision."
Approximately 17,000 Waste Management collection vehicles are equipped with Lytx DriveCams.


text:
Q: Highlighting and Deselection of UINavigationController Most iPhone apps that I use have a very subtle but slick behavior when using a navigation flow.  When you return to the previous view, the selected item immediately deselects so you get a brief un-highlighting.  This tells the user which item they just edited/viewed.
My problem is that my own application does not exhibit this behavior.  I set it up in xcode 4.2 using mostly segues, but with some code behind.
I've narrowed it down to the fact that i am using reloadData in viewWillAppear.  But I need to reload this on return from a modal which I use to add items to the list.
How/where should I be reloading my list so that it includes the new item but does not stop the deselect/highlight pattern from working?

A: I'm guessing the deselection uses the default animation duration of 0.25f so why not in viewDidAppear: use:
[self.tableView performSelector:@(reloadData) withObject:nil afterDelay:0.25f];

I'm sure there will be a better way though

A:
I need to reload this on return from a modal which I use to add items to the list.

Reloading the entire table is conceptually simple, but a better solution might be to call -insertRowsAtIndexPaths:withRowAnimation: to add the new rows to the table. That should allow the deselection animation to proceed normally, and you may also get a nice animation as new rows are inserted.

A: Do these steps.
Declare an int value "selectedCell" in .h file and assign -1 in viewDidLoad: method.
In
 - (UITableViewCell *)tableView:(UITableView *)tableView cellForRowAtIndexPath:(NSIndexPath *)indexPath

method, do
if (indexPath.row==selectedCell){
cell.selected=YES;
}

And in
- (void)tableView:(UITableView *)tableView didSelectRowAtIndexPath:(NSIndexPath *)indexPath

method, do
selectedCell=indexPath.row;

It will make the selected row highlighted always.

redpajama_set_name: RedPajamaStackExchange


Missed Opportunity for a Wolf Spider Joke.
The truly sad thing about this is that it's still probably better than anything I could draw.
Hey, when I get upset at someone, I draw myself as some sort of cyborg Thomas the Tank Engine character and post my grievances on the internet for all to see too.


Facts and figures can help tremendously when you're trying to explain why Every Can Counts. If you can get information from your recycling company or facilities management department on how many cans you are saving you can use this to encourage colleagues to keep recycling.
Based on figures we collected in 2010 we know that the 'average' employee recycles 4 drinks cans a month. Use this stat across the number of people who work at your place to illustrate how you could all make your cans count. You could even set some targets, and make people quickly see the difference that saving their cans for recycling could make.
Distance: work out how far the cans you've recycled would stretch if laid end to end. It could be from here to London, Paris or New York. Or even the moon!
This is a really good way of making recycling relevant.
The recycling process for drinks cans saves up to 95 per cent of the energy needed to make aluminium or steel from raw materials. Put another way, with the energy needed to make one aluminium can from raw materials, 20 could be made using recycled aluminium.
Here are some more facts. Once you know how many cans you are saving at work by recycling, you will be able to put together some very powerful statistics to make your colleagues really see the importance of recycling.
We are always working to add more ideas and suggestions to this website – and that's we're you come in. If you'd like to share any ideas for promoting recycling with us and other recycling champions around the UK, then we'd really like to hear from you. It could be an event you've run, a competition you've designed or some great coverage you've got in the company or local newsletter. Please let us know what works for you – it could help others make Every Can Count! Just drop us a line and we'll do the rest.
And don't forget you can contact us for additional information and advice too!
We're developing new resources to support recycling champions everywhere, but to help us understand the challenges of recycling at work we're looking to recruit some experts to give us some insight and share their experiences.


Have the German and Chinese economies been able to perform better compared to other world economies because they have retained their industrial bases, instead of outsourcing production and turning to investment banking to support growth?
Yishan Wong, Quantity has a quality all its own.
It's not clear that this is true.
How far should you go to protect a stranger's laptop?
Protecting a stranger's laptop carries the same moral obligation as upholding the sanctity of private property rights when you yourself have no personal interest in that property.
Therefore, you should protect a stranger's laptop with the same zeal and vigor that a libertarian would work to protect the abstract notion of property rights.


Sky Sports pundit Guillem Balague has dismissed rumours that Liverpool manager Jurgen Klopp could be set for a switch to Real Madrid.
The German coach has been linked with the position as pressure grows on Zinedine Zidane, with his side 17 points behind Barcelona in La Liga.
But Balague has made clear his view that Real Madrid will have to look elsewhere if they are searching for a new manager in the imminent future.
"Jurgen Klopp has even been mentioned," Balague told Sky Sports. "Klopp will stay at Liverpool though because he's somebody that wants to stay for seven years at Anfield as we read in the Raphael Honigstein book.
Tottenham boss Mauricio Pochettino has also been linked with a move to the Spanish capital, as has Germany coach Joachim Low, and Balague gave his verdict on both.
"Everybody in Spain is mentioning Mauricio Pochettino but I keep saying it just doesn't make sense," Balague added.
"He's taking Tottenham into a new stadium and a new era. There's a plan there and of course he has no buyout clause so Real would have to convince Daniel Levy to let him go. It doesn't make much sense in my eyes.
Zidane's future could be heavily dependant on how Real Madrid fare in the Champions League. They currently lead Paris Saint-Germain 3-1 after last week's last-16 first leg at the Bernabeu.


text:
Canonical Residence
Christ Church Cathedral Dublin > Worship > Services
Monday-Friday, 10.00 am: Morning Prayer
Monday-Friday, 12.00 pm: Peace Prayers
Monday-Friday, 12.45 pm: Eucharist
Monday and Friday, 5.00 pm: Said Evening Prayer
Tuesday, 6.00 pm: Compline, sung by a consort of Cathedral Lay Vicars Choral (during term time)
Wednesday, 6.00 pm: Choral Evensong, sung by the Girl Choristers (during term time)
Thursday, 12:45pm: Eucharist, service for healing with the opportunity to receive individual prayer for healing
Thursday, 6.00 pm: Choral Evensong, sung by the Cathedral Choir (during term time)
Saturday, 5.00 pm: Compline, sung by a consort of Cathedral Lay Vicars Choral (during term time)
Sung service times may vary, especially out of cathedral choir terms. Please check the current music list for further details: Current Music List.
11.00 Funeral Service for Frederick McKeown, Dean's Verger, Service sheet
17:00 Choral Evensong — sung by the choir of St Stephen's Episcopal Church, Oak Ridge, Service sheet
11.00 The Cathedral Eucharist — sung by the choir of St Stephen's Episcopal Church, Oak Ridge, Service sheet
15.30 Choral Evensong — sung by the choir of St Stephen's Episcopal Church, Oak Ridge, Service sheet
11.00 The Cathedral Eucharist — sung by the choir of St James, Los Angeles
18.00 Choral Evensong — sung by the choir of the Cathedral Church of the Redeemer, Calgary
11.00 The Cathedral Eucharist — sung by the choir of the Cathedral Church of the Redeemer, Calgary
Christ Church Cathedral is a member of the world wide Anglican Communion. People of all faiths and none are welcome at services.
*Sung service times may vary, especially out of cathedral choir terms. Please check the current music list for further details.


text:
Q: How do I change the value of a variable in an object with file handling? I am working on a project with oop and file handling and I need a changeQuantity() method where the name of the item and a number(positive or negative) is passed. I want to change the quantity with this method and write the changes to the file.
My Object:
    class Item(){
        int itemId, quantity;
        char title[25], type[10];
        float price;
        public:
            void changeQuantity(char*, int);
    };

The changeQuantity() method I am using:
    void Item::changeQuantity(char* name, int quan){
        fstream file;
        file.open("filename.txt", ios::in | ios::out);
        //after finding the object to work on
        this->quantity += quan;
        file.seekp(file.tellp() - sizeof(*this));
        file.write((char*)this, sizeof(*this));
    }

I tried with this method but it messes up the entire text file. How can I change only the quantity variable and write that change to the file without affecting anything else?????
Any kind of help would be greatly appreciated. Thank You.
PS: What I want to do here is only change the value of the quantity variable stored in the object which is stored in the txt file. The code that I am using messes the txt file.

A: I removed parameters except the file name from file.open() method. As fstream already has default parameters ios::in | ios::out, I removed that and it worked the way I wanted it to. But it does not work 100% of the time. It still repeats the problem sometimes and I haven't been able to find that out why.

A: It seems like you are mixing apples and oranges.  You read something from a text file of size *this; but you read it into the binary storage of your object, and in binary mode.  When it is written out, it is still in the binary format of your object.  Ways to do it right:

*

*Open the file in text mode, and read and write everything with, say gets & puts (insecure and error prone).  Translate every number from text to binary when reading it in.

*It is better to read them into std::string variables; as it is more powerful and less error prone.  The classic C++ way to do it is e.g. the example from Input/output with files:

// reading a text file
#include <iostream>
#include <fstream>
#include <string>
using namespace std;

int main () {
  string line;
  ifstream myfile ("example.txt");
  if (myfile.is_open())
  {
    while ( getline (myfile,line) )
    {
      cout << line << '\n';
    }
    myfile.close();
  }

  else cout << "Unable to open file";

  return 0;
}

You would need to adapt it to read and translate (e.g. from text number format to a variable) each member of your object.  I don't know of a way to mass read e.g. lines of text in a text file into an object's members.  Once it is in binary format and properly read into your object, you can write our objects out to a binary file like that; but note: they won't be of fixed size, so you will need to write the size of the object out first, and then the object itself; and read the size of the object in and then the object itself.
In short, you are using a binary file access method, when e.g. your ints are text instead of probably 32-bit binaries, and your strings are are \n or \n\r instead of null terminated.  Typical ways to handle text input and output of objects are to have one text line for each member, and translate them one at a time; or to read and write them as CSV or JSON - again one at a time for each member; and then looping through the file.
BTW: It is considered bad form to use using std; as in this example.  To keep things in the std namespace from interfering with your variables and routines, it is better to use using std::string; etc.; for each thing you want to access from the std namespace.


text:
American Baptist World Mission Conference
Chuck & Barbara Chicks
200 YEARS AND COUNTING!
American Baptist International Ministries (IM) celebrated its 200th anniversary in late July by hosting a special World Mission Conference at Green Lake Conference Center in Green Lake, Wisconsin. The American Baptist Foreign Missions Society, which began in 1814 and is now known as International Ministries, has Baptist partners in 74 countries. Three SCFBC members, Gladys McFarland and Chuck and Barbara Chicks attended this spectacular event along with hundreds and hundreds of other participants from across the nation and around the world.
All IM missionaries were brought to the US and more than 100 leaders from IM partners and worldwide Baptist groups came as invited guests. The workshops and meals together allowed opportunities to meet and speak with missionaries, fellow Baptists and guests from many nations. Bible studies, worship services and evening programs featured a different area of the world each day: Asia; Africa and the Middle East; Ibero-America and the Caribbean; Europe. These gatherings were held in a 1200 seat tent which was often full.
The morning devotions were given by new missionaries who are preparing to go to various missionfields. They included three families who each have four young children. One such family, Kyle and Katrina Williams and children, will be going to The Democratic Republic of the Congo to work with Glen and Rita Chapman, missionaries supported by SCFBC. Glen is looking forward to their arrival.
It was exciting to learn about all the places where IM missionaries serve and the various types of ministries they perform. Some train new pastors, some work in agriculture, others are doctors or nurses, teachers, or workers with women. Many do several jobs as they live, educate and work with the nationals, equipping them to continue God's work in their own country and culture.
As an illustration of various forms of worship, the conference concluded with a Georgian Eucharistic Liturgy, led by the Baptist Bishop from the country of Georgia -- a very different communion service.
Gladys, Barbara and Chuck would be glad to share more about this inspiring conference with you.
The Celebrate!
Pastoral Search Committee Progress
Worship in the Park
Mexico School Outreach
The 5x5 Project
Forever Treasure
The Youth Did What??
Book Nook and Library Corner
Kards4Soldiers
Fall Rummage Sale


Wildly popular in the early 2000s, Pilates is enjoying a bit of a renaissance. Combining bodyweight training and yoga-inspired moves, Pilates can help improve stability, while toning your body all over,. Plus, Pilates is a great way to get fit anywhere — at home, in the gym or even at the park.
These six exercises make for an excellent upper-body and shoulder workout, helping you gain strength to complete everyday tasks (carrying groceries, lifting things). As a bonus, they can also help alleviate shoulder and back pain, too.
Start on a mat in push-up position.
Keeping your hips level, lift your left hand off the floor and bend your left elbow behind you so your hand is next to your shoulder.
Return to the starting position, then repeat, this time rotating your hips until they are perpendicular with the ground.
Return to the start position, then repeat 20 times for one set, alternating sides. Aim for three sets.
Sit on the floor with your knees bend and your hands and feet flat on the ground.
Lean your torso back 45 degrees.
Bring your left knee to your chest, putting your left foot on top of your right knee, then lift your hips off the ground.
Return to the starting position, then repeat on the opposite side.
Do 20 reps for a full set. Aim for three sets.
These are similar to normal push-ups, but with only one foot on the ground.
Start in a push-up position, then lift your right leg off the ground.
Hold it in the air while you do partial push-ups, only going down a few inches and keeping your elbows pointed directly behind you.
Do 10 reps, then switch legs and do 10 more for one set. Aim for three sets.
Start in a plank position, with your forearms flat on the ground and your elbows under your shoulders.
Rock your body forward, bending your elbows until your face nearly touches the floor.
Press backwards to the starting position.
Repeat 20 times for one set. Aim for three sets.
Lie on your back with your legs bent and your feet flat on the floor, hip-distance apart.
Reach your hands toward the ceiling, palms in.
Keep your head down as you inhale and reach your shoulders off the mat, stretching up, then exhale as you pull your shoulders back down.
This is a great exercise to help with shoulder pain. Aim for three sets of 20 reps.
Start in the same position as the scapula isolation, but with your hands at your sides.
Tuck your chin toward your chest, then slowly lift your head off the mat, following through the motion of the chin tuck.
Lower your head back to the start position, and repeat 10 times.
Do this exercise slowly and carefully to relieve pain from neck injuries.


I saw the graffiti pictured while walking around Maastricht, in The Netherlands, back in April. I took a photo of it because it was something that piqued my interest in that moment, and also because I knew at some point I would want to write about it.
I'm not usually a big fan of graffiti sayings, or bumper sticker sayings, because they tend to be pithy, and lack any substance. Also, because I have found that many people who make a show of such sayings do not, in fact, live them. I mean really, if you have "Coexist" on your bumper at the same time you refer to people with a different ideology as you as being sub-human, then how serious can I take you?
All that being said, I did like this one because it serves as a reminder of something that I think all of us, but especially survivors, tend to forget.
Healing is a long journey. It's easy to see what you think is the end result of healing, whatever that looks like for you, and measure yourself by the fact that you aren't there yet. I'd disagree with that. Not that you shouldn't have an eye on the prize, so to speak, but you need to see the details, and you need to enjoy the details.
If healing is a long journey, then there are many details. You don't take a long drive by looking up the destination on a map, setting out, and getting there. No, you have to figure out the route from here to there, where to turn, where to stop, when to take a break and so on. Each one of those things is part of your journey, and another step toward the goal. If you don't enjoy the steps, if you don't count the small victories, then the journey can drag on and on, becoming overwhelming to us.
How much better would you feel if you could look at the details, and enjoy the progress you've made?
How much better would your life be if you could stop every once in a while, and simply look at the details, instead of always being focused on the abuse? See the flowers, laugh with your loved ones, watch the sun set, play a game, or just sit and be with yourself. There are a lot of really great details all around us every day. Don't get so bogged down in your past, and healing, that you miss them.
It's OK to enjoy something for no other reason than that you enjoy it.
It took me a long time to learn, and accept, that. So I missed out on a lot of details. Don't make the same mistake.
Kathleen Esslemont liked this on Facebook.


text:
Homepage / Roblox / Roblox Airplane Story Secret Ending
Roblox Airplane Story Secret Ending
What ending that you ever choose in Airplane game series? Or you totally do not know the kind of ending in Airplane game series, do you? Of course, knowing the all endings in this Airplane series game is totally a must for you. This can be a parameter for you to choose the best ending of playing this game. So, are you familiar with the secret ending?
Before we go on explaining the secret ending in bundle, it is absolutely better for you to know about the game first. However, by learning and understanding about the goal of a game, automatically, you will get a step easier in playing it. So, how about the game and what make it so interested to play?
The Airplane is a game series that allow the player to be a civilian flight. The game actually focuses in telling a story of civilian flight after a vacation. This Airplane game is involved into a horror game-genre that is successful to attract the player. However, most of player really loves for the horror game. This kind of game offers the great challenge for them. So, it is no wonder if lots of Roblox player prefer this game than others.
This awesome game was created on August 2019 by Ponchokings as the creator of the game. This game has been divided into some endings with different goal. Need to know that every ending has a certain mission and different from other endings.
The characters of this game are divided into five roles. Here they are:
The Players as civilian flight
The Crew on Airplane
The Airport Crew
Then, talking about the secret ending, definitely we will focus on the story of game, how to access and the plot.
What is the secret ending?
Need to know that the secret ending is in the Airplane 1 series. As the name, the secret ending happens secretly in Airplane. The goal of this ending is to give the exclusive badge as the rewards after completion.
How to access it?
Then, to choose this ending of the game, a portal will appear in the back right corner of the plane during the Snake Challenge. Then, entering the portal will lead to the Secret Ending, as a black space with Monster in the back.
How is the plot of this game?
This ending starts when the monster introduce himself as Ronald and talk that he was once a human too. Then, he said that he suffered a heart attack and died on a plane as the one player is on and the player is there.
The monster expresses his anger which none try to save him as well. Then, everyone moves on as if it did not happen. Then, the monster decides a fair trade for a soul and set fire to the players in the ending. Then, the story will end when Ronald say that it is not the end story.
Well, those are the topic about the secret ending that we can share to you. If you want to get the real ending, definitely you should try this ending. Good Luck!!!
Previous post Roblox Airplane All Endings
Next post Roblox Free Abs T-shirt


text:
King Prawn ist eine englische Crossover-Band aus London, die 1993 gegründet wurde, sich 2003 auflöste und seit 2013 wieder aktiv ist.

Geschichte
Die Band wurde 1993 gegründet und bestand aus dem Sänger Al-Farabi Rumjen, dem Bassisten Babar Luck, dem Gitarristen Roger "Devil" Hands und dem Schlagzeuger Nick "Swindonboye" "Slugboy" Smith. Nach ihrem ersten Auftritt in The Garage im Norden Londons erreichte die Band einen Plattenvertrag bei Words of Warning Records. Ende 1995 wurde mit Poison in the Air daraufhin eine erste Single veröffentlicht. Noch im selben Jahr erschien das Debütalbum First Offence, das von Martin Ivor Kent von Skunk Anansie produziert worden war. Da das Album recht erfolgreich war, konnte die Gruppe einige Fans nicht nur in London, sondern in ganz Großbritannien dazugewinnen. Nach der Veröffentlichung folgten Auftritte zusammen mit Citizen Fish, Snuff, Agnostic Front und Madness. Anfang 1997 erschien die Single Depths of My Soul, der kurz darauf Not Your Punk folgte. Im Januar 1998 wurde nach einjähriger Schaffenszeit das Album Fried in London veröffentlicht. Produziert hatte es der durch seine Arbeit mit Therapy? bekannt gewordene Harvey Birrell. In weiteren Konzerten empfahl sich die Band einem größeren Publikum. Bei den Kerrang! Awards 1998 wurde die Band außerdem in der Kategorie "Best New British Band" nominiert. Außerhalb ihres Heimatlandes erschien das Album erst Ende Juli 1998. Anlässlich dieser Reichweitenausdehnung wurde für die Ausstrahlung auf MTV ein Videoclip zu Dephts of My Soul gedreht. Im folgenden Jahr erschien mit Your Worst Enemy eine EP, der im Jahr 2000 die Single Day in Day Out folgte. Im August 1999 war das Album Surrender to tbe Blender aufgenommen worden und wurde im Jahr 2000 veröffentlicht. Im selben Jahr wurde mit Someone to Hate eine Single ausgekoppelt, die insgesamt drei Lieder enthält. Ende 2001 wurde innerhalb von vier Wochen das Album Got the Thirst aufgenommen, ehe es im Sommer 2002 auf Tournee durch Italien und Deutschland ging. 2003 wurde Got the Thirst veröffentlicht. Die Band hielt ihren vorerst letzten Auftritt am 20. Dezember 2003 in London ab. Das Konzert wurde als DVD herausgebracht. Grund für die Auflösung war zum einen, dass die Bandmitglieder nicht mehr gewillt waren zu touren, zum anderen hatte Roger Hands einen anderen Job gefunden. Seit 2013 ist die Band wieder aktiv. Im selben Jahr war die Gruppe auf den Reading and Leeds Festivals und dem Boomtown Festival zu sehen. Im November des Jahres veröffentlichte die Band via Bandcamp die beiden neuen Lieder Done Days und A Solemn Man. 2015 und 2017 spielte die Band erneut auf dem Boomtown Festival.

Stil
Laut Mario Mesquita Borges von Allmusic vermischt die Band Ska, Punk und Hardcore Punk, sodass daraus eine alternative Form des Rock 'n' Roll geschaffen werde. Christian Graf gab in seinem Nu Metal und Crossover Lexikon an, dass die Band Punk, Ska, Reggae, Hip-Hop, Metal und Jazz vermischt. Dieselben Genres nannte auch Joel McIver in seinem Buch The Next Generation of Rock & Punk Nu-Metal. Im Interview mit derdude-goes-ska.de gab die Band an, dass sie neben Punk und Hip-Hop auch durch Dub und Jungle beeinflusst wurde. Alex Henderson, ebenfalls von Allmusic, stellte in seiner Rezension zu Got the Thirst fest, dass King Prawn eine der spannendsten Ska-Punk-Bands war, die die 1990er Jahre hervorgebracht hätten. Das Album nun sei eine solide Fortsetzung und es seien weiterhin Einflüsse von Bands wie The Specials, den Dead Kennedys, The Clash, Rage Against the Machine, Public Enemy und Shabba Ranks hörbar. In ihren Songs nehme die Band den Ska-Punk als Grundlage und reichere ihn mit Hardcore Punk, Alternative Metal, Hip-Hop, Funk, Soul und Dancehall an.

Die "abwechslungsreiche Mischung aus Oi!, Punk & Ragga-Ska" ergebe einen "MultikultiCore", der tanzbar und vergnüglich sei, meinte Hanno Kress in ihrer First-Offence-Besprechung für das Rock Hard. Er komme  Dub War und Blaggers ITA nahe. Die Texte seien anarchistisch. Simon Brunner vom ox-Fanzine schrieb in seiner Rezension zu First Offence, dass es sich bei King Prawn um eine Crossover-Band handelt, die Hardcore, Ska-Punk, Ragga, Dub sowie etwas Funk und Hip-Hop kombiniere. Dies würden bei ihm Vergleiche zu Dub War, Fishbone, Red Hot Chili Peppers, Rage Against the Machine und aufgrund des Gesangs auch zu Blue Meanies, Dead Kennedys und System of a Down hervorrufen. In derselbe Ausgabe rezensierte Brunner auch Fried in London und stellte fest, dass diese Veröffentlichung nicht mehr ganz so vielfältig ist. Man orientiere sich ausschließlich in Richtung Punk, Hardcore Punk, etwas Metal und vor allem Reggae, Ragga, Ska und Dub, sodass es etwas mehr nach Bad Brains und Dub War klinge, nur "modern und fett produziert". Die Genres würden in den Songs recht schnell wechseln, jedoch würden sie eingängig bleiben. Die beiden Bonuslieder dieser Wiederveröffentlichung würden an Blue Meanies erinnern. In einer späteren Ausgabe rezensierte Brunner Got the Thirst und merkte an, dass die Lieder durch den Hip-Hop-Anteil altbacken klingen. Die Lieder seien sehr abwechslungsreich, jedoch überwiege der Hip-Hop mit harten Gitarren im Stil der Red Hot Chili Peppers und von Rage Against the Machine, allerdings würden die Songs durch die Blasinstrumente einen eigenen Charakter erhalten.

Diskografie
 1995: Poison in the Air (Single, Words of Warning Records)
 1995: First Offence (Album, Words of Warning Records)
 1997: Not Your Punk (Single, Words of Warning Records)
 1997: Depths of My Soul (Single, Words of Warning Records)
 1998: Fried in London (Album, Words of Warning Records)
 1999: Your Worst Enemy (EP, Spitfire Records)
 2000: Day in Day Out (Single, Spitfire Records)
 2000: Someone to Hate (Single, Spitfire Records)
 2000: Surrender to the Blender (Album, Spitfire Records)
 2003: Got the Thirst (Album, Golf Records)
 2003: The Dominant View (Single, Golf Records)
 2005: Live at the Forum 20.12.03 (DVD, Golf Records)
 2013: Done Days / Solemn Man (Single, Yo-Silver Records)

Weblinks

Einzelnachweise

Crossover-Band
Englische Band
Hardcore-Punk-Band
Hip-Hop-Gruppe
Metal-Band
Band (London)
Punkband
Ska-Punk-Band

redpajama_set_name: RedPajamaWikipedia